VALBIOTIS announces the success of the capital increase with maintenance of the Shareholders’ Preferential Subscription Right, for an amount of 7.2 M€.
VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.